EGFR and anemia: Concerning the safety profile, our study, showed a significant higher incidence of AEs in the group of patients treated with R/T in comparison to anti-EGFR-based therapy (p 0.018), and a drug-specific toxicities (hand-foot syndrome and hypertension for R, neutropenia and anemia for T, folliculitis for anti-EGFR), as previously reported.